Table 2 Correlation between serum CA15-3, CEA and SF in canine mammary gland tumor and clinicopathological parameters.
From: Combined detection of CA15-3, CEA, and SF in serum and tissue of canine mammary gland tumor patients
Clinicopathological parameters | Number (%) | CA15-3 (U/mL) | CEA (ng/mL) | SF (ng/mL) |
|---|---|---|---|---|
Age* | ||||
≤ 10 years | 33 (58.8%) | 9.757 ± 5.832 | 28.52 ± 19.07 | 609.9 ± 236.5 |
> 10 years | 23 (41.2%) | 10.06 ± 5.850 | 26.20 ± 18.51 | 497.4 ± 217.3 |
P-value | 0.335 | 0.203 | 0.863 | |
Tumor location* | ||||
Multiple | 24 (42.4%) | 10.11 ± 6.079 | 25.67 ± 18.08 | 549.5 ± 247.8 |
Single | 32 (57.6%) | 8.711 ± 4.651 | 28.99 ± 19.33 | 574.3 ± 224.9 |
P-value | 0.067 | 0.445 | 0.201 | |
Tumor mass size# | ||||
T1 (< 3 cm) | 12 (21.4%) | 11.23 ± 6.506 | 28.29 ± 18.53 | 611.2 ± 224.8 |
T2 (3–5 cm) | 28 (50.0%) | 10.18 ± 5.779 | 26.21 ± 17.82 | 580.5 ± 244.8 |
T3 (> 5 cm) | 16 (28.6%) | 8.359 ± 5.044 | 29.39 ± 20.66 | 498.7 ± 211.4 |
P-value | > 0.05 | > 0.05 | > 0.05 | |
Lymph node involvement* | ||||
N0 | 41 (73.2%) | 8.235 ± 5.364 | 21.88 ± 16.41 | 498.7 ± 227.3 |
N1 | 15 (26.8%) | 14.39 ± 4.588 | 43.09 ± 16.27 | 738.8 ± 159.8 |
P-value | < 0.01 | < 0.01 | < 0.01 | |
Metastasis* | ||||
M0 | 44 (78.6%) | 8.312 ± 4.747 | 22.83 ± 17.64 | 508.8 ± 222.8 |
M1 | 12 (21.4%) | 15.64 ± 4.902 | 44.94 ± 11.76 | 765.1 ± 157.7 |
P-value | < 0.01 | < 0.01 | < 0.01 | |
Histologic grade# | ||||
I | 21 (37.5%) | 7.659 ± 4.705 | 20.72 ± 15.21 | 497.3 ± 199.9 |
II | 25 (44.6%) | 9.173 ± 5.114 | 27.09 ± 20.26 | 535.4 ± 238.3 |
III | 10 (17.9%) | 16.33 ± 5.103 | 43.14 ± 11.94 | 773.9 ± 169.9 |
P-value | < 0.05 | < 0.05 | < 0.05 | |
